Challenges in Using Progestin to Prevent Singleton Preterm Births: Current Knowledge and Clinical Advice
David B Nelson,Yevgenia Y Fomina
DOI: https://doi.org/10.2147/ijwh.s394305
2024-01-23
International Journal of Women s Health
Abstract:David B Nelson, Yevgenia Y Fomina Division of Maternal-Fetal Medicine, Department of Obstetrics and Gynecology, University of Texas Southwestern Medical Center, Dallas, TX, USA Correspondence: David B Nelson, Division of Maternal-Fetal Medicine, Department of Obstetrics and Gynecology, University of Texas Southwestern Medical Center, 5323 Harry Hines Boulevard, H6.106, Dallas, TX, 75235, USA, Email Preterm birth is the leading cause of infant morbidity and mortality in children younger than 5 years old and accounts for approximately 35% of newborn deaths worldwide. The use of progestogen therapy for prevention of preterm birth has been one of the most controversial topics in modern obstetrics. Progestogens can be classified as natural or synthetic. Progesterone is a natural progestogen while progestins such as 17-alpha-hydroxyprogesterone caproate (17OHP-C) are synthetic steroid hormones. Evidence supporting the use of progestogens varies by formulation and populations studied. After more than a decade, the US Food and Drug Administration has withdrawn accelerated approval of 17OHP-C for the prevention of recurrent preterm birth in pregnant individuals with a singleton gestation. With this decision, there is no current FDA-approved treatment for prevention of spontaneous preterm birth. In this review, we provide a historical context behind the rise and fall of 17OHP-C clinical application, highlight the challenges behind the data supporting progestogen use, and offer suggestions on how to make an impact on preterm birth moving forward. Keywords: accelerated approval, anxiety, FDA, healthcare costs, Makena ® , National Institute of Health, neonatal morbidity and mortality, pregnancy, preterm birth, progestin, progestogen, progesterone, spontaneous preterm birth, 17-alpha-hydroxyprogesterone caproate Preterm birth is defined by the World Health Organization (WHO) as delivery prior to 37 weeks of gestation based on the obstetric estimate. 1 In the United States (US), 66% of infant deaths in 2018 occurred in preterm infants, with the infant mortality rate at less than 28 weeks 186 times higher than at 37 to 41 weeks. 2,3 Infants born preterm with low-birthweight and survive have significantly higher risks of both short- and long-term morbidity and mortality. 4 The frequency of these tragedies is inversely related to gestational age. For example, the incidence of cerebral palsy for infants born prior to 28 weeks is 15% as compared to 0.13% at term. 5,6 Beyond the neonatal period, survivors of PTB also have increased risks of chronic diseases, such as elevated blood pressure, heart failure, chronic kidney disease, diabetes, and obstructive lung disease. 5 Large cohort studies report that patients born preterm have approximately 30% to 50% higher all-cause mortality between 18 and 45 years than those born full-term. 7 While early preterm births (<34 weeks) comprise the majority of severe neonatal complications, late preterm birth impacts a larger proportion of individuals and also carries neonatal risks. In a retrospective cohort study of 261,194 singletons born at 24 weeks or greater at Parkland Hospital, all measured adverse neonatal outcomes were significantly increased in the late preterm births as compared to "term" 39-week deliveries. The rate of aggregated morbidity was 34% of births at 34 weeks, as compared to 14% at 39 weeks. 8 Taken together, preterm birth translates to substantial healthcare expenditures. 9 The total societal burden of preterm birth was estimated at $25.2 billion based on the 2016 US birth cohort data. 10,11 Beyond financial costs, the emotional burden of preterm birth to patients, families, communities, and societies cannot be overstated. The rate of preterm birth in the US reached a nadir at 9.6% in 2014 but has been steadily rising since then to 10.5% in 2021 (Figure 1). The 2022 March of Dimes report card highlights the worsening state of maternal and infant health in the US and the increasing preterm birth rate. 12 More than 70% of preterm births occur between 34 and 36 weeks of gestation. The recent increase in the overall preterm birth rate is largely driven by these late preterm deliveries that rose by an average annual rate of 2% from 2014 to 2019. 13 The rate of early preterm birth, defined as births before 34 weeks of gestation, has remained unchanged at 2.8% since 2014. 1 Figure 1 Preterm birth rate in the United States over time. Adapted from March of Dimes full report card; 2022. Available from: https://www.marchofdimes.org/peristats/data?top=3&lev=1&stop=60®=99&obj=1&slev=1 . 12 Preterm birth is classified as spontaneous or medically initiated for maternal or fetal indications. It is e -Abstract Truncated-
obstetrics & gynecology